A novel nanoluciferase transgenic reporter measures proteinuria in zebrafish.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
10 2022
Historique:
received: 20 08 2021
revised: 25 04 2022
accepted: 09 05 2022
pubmed: 19 6 2022
medline: 28 9 2022
entrez: 18 6 2022
Statut: ppublish

Résumé

The zebrafish is an important animal system for modeling human diseases. This includes kidney dysfunction as the embryonic kidney (pronephros) shares considerable molecular and morphological homology with the human nephron. A key clinical indicator of kidney disease is proteinuria, but a high-throughput readout of proteinuria in the zebrafish is currently lacking. To remedy this, we used the Tol2 transposon system to generate a transgenic zebrafish line that uses the fabp10a liver-specific promoter to over-express a nanoluciferase molecule fused with the D3 domain of Receptor-Associated Protein (a type of molecular chaperone) which we term NL-D3. Using a luminometer, we quantified proteinuria in NL-D3 zebrafish larvae by measuring the intensity of luminescence in the embryo medium. In the healthy state, NL-D3 is not excreted, but when embryos were treated with chemicals that affected either proximal tubular reabsorption (cisplatin, gentamicin) or glomerular filtration (angiotensin II, Hanks Balanced Salt Solution, Bovine Serum Albumin), NL-D3 is detected in fish medium. Similarly, depletion of several gene products associated with kidney disease (nphs1, nphs2, lrp2a, ocrl, col4a3, and col4a4) also induced NL-D3 proteinuria. Treating col4a4 depleted zebrafish larvae (a model of Alport syndrome) with captopril reduced proteinuria in this system. Thus, our findings validate the use of the NL-D3 transgenic zebrafish as a robust and quantifiable proteinuria reporter. Hence, given the feasibility of high-throughput assays in zebrafish, this novel reporter will permit screening for drugs that ameliorate proteinuria, thereby prioritizing candidates for further translational studies.

Identifiants

pubmed: 35716957
pii: S0085-2538(22)00452-5
doi: 10.1016/j.kint.2022.05.019
pmc: PMC7614274
mid: EMS170654
pii:
doi:

Substances chimiques

Gentamicins 0
Angiotensin II 11128-99-7
Serum Albumin, Bovine 27432CM55Q
Captopril 9G64RSX1XD
Cisplatin Q20Q21Q62J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

815-827

Subventions

Organisme : Wellcome Trust
ID : 202860
Pays : United Kingdom

Informations de copyright

Crown Copyright © 2022. Published by Elsevier Inc. All rights reserved.

Références

Nat Metab. 2020 May;2(5):461-474
pubmed: 32694662
Dev Biol. 2005 Sep 15;285(2):316-29
pubmed: 16102746
Proc Natl Acad Sci U S A. 1990 Feb;87(4):1606-10
pubmed: 1689491
J Biol Chem. 2000 Sep 29;275(39):30716-24
pubmed: 10896941
J Cell Biol. 1996 Dec;135(5):1403-13
pubmed: 8947561
EMBO J. 1988 Sep;7(9):2687-95
pubmed: 2846280
Sci Rep. 2016 Oct 11;6:35068
pubmed: 27725732
Dev Dyn. 2005 Oct;234(2):244-54
pubmed: 16110506
Kidney Int. 2003 Feb;63(2):438-46
pubmed: 12631109
Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):2958-2963
pubmed: 28246329
PLoS Genet. 2007 Oct;3(10):1922-38
pubmed: 17953490
Am J Physiol Renal Physiol. 2005 May;288(5):F923-9
pubmed: 15625083
Int J Cancer. 1997 Jul 3;72(1):43-9
pubmed: 9212221
Nat Neurosci. 2007 Dec;10(12):1529-37
pubmed: 17982451
Pediatr Nephrol. 2022 Dec;37(12):3105-3115
pubmed: 35278129
Am J Physiol Renal Physiol. 2015 Sep 15;309(6):F531-9
pubmed: 26202224
J Physiol. 2014 Sep 15;592(18):4013-23
pubmed: 25107927
Genes Dev. 1996 Dec 1;10(23):2981-92
pubmed: 8956999
Nat Rev Mol Cell Biol. 2002 Apr;3(4):256-66
pubmed: 11994745
Kidney Int. 2009 Nov;76(9):968-76
pubmed: 19710627
Mol Med Rep. 2014 Feb;9(2):457-65
pubmed: 24337247
Dev Cell. 2018 Jul 2;46(1):112-125.e4
pubmed: 29974860
Kidney Int. 2016 Jun;89(6):1204-10
pubmed: 27165832
Nat Rev Nephrol. 2017 Aug;13(8):455-470
pubmed: 28669993
Results Probl Cell Differ. 2017;60:55-75
pubmed: 28409342
Dev Dyn. 1995 Jul;203(3):253-310
pubmed: 8589427
J Vis Exp. 2015 Feb 20;(96):e52540
pubmed: 25742415
Nat Protoc. 2008;3(1):59-69
pubmed: 18193022
J Biol Chem. 1988 Nov 25;263(33):17217-20
pubmed: 3182844
J Am Soc Nephrol. 2000 Feb;11(2):191-202
pubmed: 10665926
Kidney360. 2020 Jul 16;1(9):936-942
pubmed: 35369551
J Biol Chem. 1999 Jan 8;274(2):717-27
pubmed: 9873007
J Morphol. 2016 Aug;277(8):1104-12
pubmed: 27185367
Methods Cell Biol. 2010;100:233-60
pubmed: 21111220
Kidney Int. 2020 Jun;97(6):1150-1163
pubmed: 32061435
PLoS Genet. 2015 Apr 02;11(4):e1005058
pubmed: 25838181
Pediatr Nephrol. 2019 May;34(5):751-762
pubmed: 29502161
Hum Mol Genet. 2012 Apr 15;21(8):1744-59
pubmed: 22210625
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
Am J Physiol. 1992 Oct;263(4 Pt 2):F601-6
pubmed: 1415732
J Cell Sci. 2006 May 15;119(Pt 10):2127-37
pubmed: 16638803
Development. 1998 Dec;125(23):4655-67
pubmed: 9806915
Clin J Am Soc Nephrol. 2008 Sep;3(5):1430-6
pubmed: 18480301

Auteurs

Richard W Naylor (RW)

Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

Emmanuel Lemarie (E)

Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Anthony Jackson-Crawford (A)

Department of Blood Sciences, Grange University Hospital, Llanyravon, Gwent, UK.

J Bernard Davenport (JB)

Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

Aleksandr Mironov (A)

EM Core Facility (RRID: SCR_021147), Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Martin Lowe (M)

Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. Electronic address: martin.p.lowe@manchester.ac.uk.

Rachel Lennon (R)

Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; Department of Paediatric Nephrology, Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. Electronic address: rachel.lennon@manchester.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH